Category Archives: Industry

Industry news on LLLT, Low Level Laser Therapy, Cold Laser, Laser Biostimulation, LEPT Low Energy photon Therapy, LILT Low Intensity Laser therapy, Photobiomodulation, Photostimulation, Laser Therapy

THOR laser in UK National Health Service (NHS) clinical trial for treatment of Oral Mucositis

Laser therapy to ease cancer treatment side effects | ITV News

MPH LiTFORM ITV news release Sept 2018

Read more on Photobiomodulation Therapy for reducing severity and duration of oral mucositis.

Posted in Industry, THE FUTURE OF LLLT | Leave a comment

Shining a Light on PBM & The Health Care Innovation Ecosystem

By Ms. Hannah M Clark, Global NetGeneration of Youth Cyberjournalist, with support from Dr. Ronnie Lowenstein, Executive Director Global NetGeneration of Youth

NGY Cyberjournalist Hannah Clark being inspired by the passion of Mr. James Carroll, founder and CEO of THOR Medicine.Recently, I was honored to be invited by Dr. Robert Boege, Executive Director of ASTRA to join ASTRA’s Futurist Dr. Ronnie Lowenstein, and serve as a NetGeneration of Youth Cyberjournalist covering a Congressional Briefing held in the Rayburn House Office Building on October 11, 2018 entitled, “Ending Opioid Use: A New Hope”.  The event was co-sponsored by ASTRA, The World Association for Laser Therapy, NetGeneration of Youth, The Optical Society of America, and thirteen other science and medical … Continue reading

Posted in Industry, THE FUTURE OF LLLT | Leave a comment

New Technologies, Treatments Can End Opioid Use

Those suffering from America’s opioid crisis recently received two major messages of hope.

On Oct. 24, President Donald Trump signed the Opioid Crisis Response Act (OCRA) into law. Dozens of bills designed to address the diverse aspects of the opioid crisis were consolidated into one strategic and integrated approach.

OCRA received overwhelming bi-partisan support in both Chambers.

HR6, which is now Public Law 115-2716, broke new ground in being the first legislation to mandate aggressive development and adoption of alternative pain treatments that include “innovative medical technologies for pain management.”

On Oct. 11, Congress held its first ever briefing on ending opioid use through … Continue reading

Posted in Industry, THE FUTURE OF LLLT | Leave a comment

THOR CEO leads official US Congressional Briefing on Photobiomodulation (PBM)

Washington DC, 11th October, 2018. James Carroll (CEO, THOR Photomedicine), Prof. Praveen Arany (University at Buffalo, NY), Annette Quinn RN (Program Manager, Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced Photobiomodulation (PBM) to a large gathering of senior policy officials at the Rayburn House Office Building.

James Carroll presented evidence to Congress on the effectiveness of PBM for treating pain and where it can be used in place of opioids. Prof. Praveen Arany explained how and why it works, and Annette Quinn RN gave her first hand experience in treating over 854 patients with Oral Mucositis.

The briefing was a historic step for PBM, moving the conversation forward as members of congress were shown stories by members of the … Continue reading

Posted in Industry, THE FUTURE OF LLLT | Leave a comment

LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

LumiThera's Valeda® Light Delivery SystemLumiThera Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, announced a distribution agreement with Optos Plc, a division of Nikon, Inc., Japan to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in 12 European countries. Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care. The announcement follows the recent CE Mark Certification for the European Union (EU) for the treatment of dry AMD utilizing LumiThera’s Valeda™ Light Delivery System.

“The Distribution agreement with Optos allows LumiThera to begin commercialization … Continue reading

Posted in Industry | Leave a comment

LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the EURETINA

LumiThera LT-300 Light Delivery SystemLumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and diseases, announced that it will participate in the combined exhibition of the 18th EURETINA Annual Meeting and the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held in Vienna, Austria from the 20th to the 26th of September 2018.

EURETINA actively promotes new diagnostic developments, advances in vitreoretinal surgery, the development and application of new drugs, and changes in the treatment of macular degeneration.

LumiThera will debut the Valeda™ Light Delivery System for the treatment of dry AMD in the exhibition hall and will host a … Continue reading

Posted in Industry | Leave a comment

LumiThera LT-300 Device for treating Dry Advanced Macular Degeneration granted CE Mark

LumiThera LT-300 Light Delivery System“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”

“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of … Continue reading

Posted in Industry | 2 Comments